pityriasis%20(tinea)%20versicolor%20(pediatric)
PITYRIASIS (TINEA) VERSICOLOR (PEDIATRIC)
Pityriasis (tinea) versicolor is a benign, superficial, common fungal infection localized to the stratum corneum.
It occurs most commonly in postpubertal individuals when the sebaceous glands are the most active.
Facial involvement is common in adolescents, but lesions are also found on the upper trunk, neck, arms, dorsum of the hand and pubis.
Patient presents with erythematous, hypo- or hyperpigmented macules or patches that may have a slight scale.
It is caused by the lipophilic yeast Malassezia furfur.

Pityriasis (Tinea) Versicolor (Pediatric) Drug Information

Drug Information

Indication: Relief of external thrush symptoms.

Indication: Dermatophytes or yeasts, mycoses & other fungi eg, Tinea capitis, corporis, manuum, barbae, cruris, pedis....

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, cruris, manus & pedis due to Trichop...

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Tinea pedis, cruris, corporis & versicolor; cutaneous candidiasis.

Indication: Acute or recurrent genital & vag candidiasis, candidal balanitis, dermatomycosis including tinea pedis, ti...

Indication: Cryptococcosis ie, cryptococcal meningitis & infections of other sites (eg, pulmonary, cutaneous). Mainten...

Indication: Fungal skin infections including candidiasis, tinea & pityriasis versicolor.

Indication: Management of superficial candidiasis & fungal skin infections eg, mucocutaneous candidiasis, dermatophyto...

Indication: Cryptococcosis. Systemic, mucosal & vag candidiasis. Prevention of fungal infection in patients w/ maligna...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Apr 2019
Using preventive zinc and micronutrient powder supplementation does not appear to improve growth in children, a recent study has found.
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).